OSTX Stock Catalyst: OS Therapies' Phase 2b Trial Achieves Primary Endpoint for Lung Metastatic Osteosarcoma

Jan 14, 2025 · 7:48pm ET

Company announces successful clinical trial results for OST-HER2.

Max move

+103.6%

High of day $8.45

Sparker timei

7:48pm ET

OSTX · Jan 14, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

OS Therapies Incorporated (OSTX) announced that its Phase 2b clinical trial for OST-HER2 has achieved its primary endpoint with statistical significance. The trial focused on the prevention of recurrent, fully resected, lung metastatic osteosarcoma.

The successful results indicate a significant advancement in the treatment options for this condition. OS Therapies now has 27,104,500 shares in free float and 35,214,400 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time OSTX sparks.

Download Sniper App →

Catch the next OSTX-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →